Inotiv, Inc. acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 million.
January 09, 2022
Share
Inotiv, Inc. (NasdaqCM:NOTV) acquired Integrated Laboratory Systems, Inc. from Sier Capital for $52.8 million on January 10, 2022.The purchase price consist of $38 million in cash and 429,118 Inotiv common shares having a value of $18 million based on the volume weighted average closing price of Inotiv shares as reported by NASDAQ for the 20 trading-day period ending on January 6, 2022. In 2021, Integrated Laboratory Systems generated revenue of approximately $20 million. Inotiv expects to retain all existing ILS employees. Edgemont Partners served as the exclusive financial advisor for Sier Capital and ILS in connection with the transaction.
Inotiv, Inc. (NasdaqCM:NOTV) completed the acquisition of Integrated Laboratory Systems, Inc. from Sier Capital on January 10, 2022.
Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
INOTIV, INC. 
